FULC
HEALTHCAREFulcrum Therapeutics Inc
AI Insight
What's Moving FULC Today?
No stock-specific AI insight has been generated for FULC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.83$15.74
$3.85
Fundamentals
Market Cap$247M
P/E Ratio—
EPS$-1.15
Dividend Yield—
Dividend / Share—
ROE-27.1%
Profit Margin—
Debt / Equity—
Trading
Volume2.8M
Avg Volume (10D)—
Shares Outstanding66.6M
FULC News
26 articles- A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And RestructuringYahoo Finance·Jun 5, 2026
- Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerYahoo Finance·Jun 5, 2026
- Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)GlobeNewswire·Jun 5, 2026
- A Look At Fulcrum Therapeutics (FULC) Valuation After Halting Pociredir And Launching A Broad ReviewSimply Wall Street·Jun 5, 2026
- FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's EndYahoo Finance·Jun 3, 2026
- Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?Stocktwits·Jun 3, 2026
- This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’Yahoo Finance·Jun 2, 2026
- Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst callsYahoo Finance·Jun 2, 2026
- Fulcrum exploring a potential sale after FDA sidelined its sickle cell drugBiopharmadive·Jun 2, 2026
- This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’Barron's·Jun 2, 2026
- FULC Stock Crashes After Hours: What Investors Need To KnowBenzinga·Jun 2, 2026
- FDA cancer-risk stance ends sickle cell drug; Fulcrum weighs optionsStock Titan·Jun 1, 2026
- FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer RiskStocktwits·Jun 1, 2026
- Fulcrum Therapeutics Discontinues Sickle Cell Disease Program After US FDA Raises Malignancy ConcernsYahoo Finance·Jun 1, 2026
- Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic ReviewYahoo Finance·Jun 1, 2026
- After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)Yahoo Finance·May 20, 2026
- Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy RecommendationMSN·May 10, 2026
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 8, 2026
- Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·Apr 28, 2026
- Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·Apr 27, 2026
- Fulcrum Therapeutics Q1 Earnings Call HighlightsMarketbeat·Apr 27, 2026
- Fulcrum (FULC) Q1 2026 Earnings TranscriptMotley Fool·Apr 27, 2026
- Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform ExpectationsAdvfn·Apr 27, 2026
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026Yahoo Finance·Apr 27, 2026
- Fulcrum Therapeutics Appoints Josh Lehrer to its Board of DirectorsYahoo Finance·Apr 27, 2026
- Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ETYahoo Finance·Apr 20, 2026
All 26 articles loaded
Price Data
Open$3.69
Previous Close$3.77
Day High$3.89
Day Low$3.69
52 Week High$15.74
52 Week Low$2.83
52-Week Range
$2.83$15.74
$3.85
Fundamentals
Market Cap$247M
P/E Ratio—
EPS$-1.15
Dividend Yield—
Dividend / Share—
ROE-27.1%
Profit Margin—
Debt / Equity—
Trading
Volume2.8M
Avg Volume (10D)—
Shares Outstanding66.6M
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—